Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ReGen Declines "Futile" 510(k) Rescission Hearing But Plans Legal Challenge

This article was originally published in The Gray Sheet

Executive Summary

ReGen Biologics says it is considering several last-ditch options to keep its collagen meniscus scaffold device on the U.S. market, but they do not include another hearing with FDA.

You may also be interested in...



Regulatory News In Brief

U.S. District Court rules in FDA’s favor on 510(k) clearance rescission. Gastroenterology & Urology Devices panel to meet in June. More regulatory news.

Regulatory News In Brief

Chlamydia/gonorrhea tests draft guidance

Regulatory News In Brief

Chlamydia/gonorrhea tests draft guidance

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029983

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel